Cofactor Genomics has launched OncoPrism-NSCLC, an RNA-based test for predicting immune checkpoint inhibitor (ICI) response in non-small cell lung cancer (NSCLC) patients.
OncoPrism-NSCLC is now validated and ready for use, expanding the clinical applications of OncoPrism. This diagnostic platform generates multidimensional immune biomarkers using Predictive Immune Modelling to improve immunotherapy response predictions.
This follows Medicare coverage for Cofactor’s OncoPrism-HNSCC test. Both tests leverage Cofactor’s Health Expression Models, combining RNA expression with machine learning to predict ICI treatment outcomes.
Recently, Cofactor Genomics published the clinical validation of the head and neck squamous cell carcinoma (HNSCC) test. It uses RNA modelling technology to predict response to immunotherapy.
OncoPrism-NSCLC is an artificial intelligence (AI)-enabled RNA test that uses pre-treatment tumour biopsies to predict response to ICI. It is processed in Cofactor Genomics’ CAP-accredited, CLIA-certified lab.
The test’s validation is based on data from 12 clinical sites in the PREDAPT trial, and 17 sites are involved in the ongoing NSCLC study.
In late 2022, Cofactor Genomics started the study of the OncoPrism assay in NSCLC.
The clinical-stage diagnostics company said the test showed a strong correlation between predictions and actual patient responses to ICI, both as monotherapy and in combination with chemotherapy.
Cofactor Genomics CEO Jarret Glasscock said: “OncoPrism-NSCLC dramatically expands the number of patients who can benefit from OncoPrism testing, as NSCLC patients are the largest patient population being treated with ICI.
“The launch of OncoPrism-NSCLC is another important step in achieving Cofactor’s goal of bringing precision medicine to all cancer patients.”
Beyond NSCLC and HNSCC, Cofactor’s national PREDAPT trial is also evaluating OncoPrism in nine additional cancers, including colorectal, breast, cervical, liver, kidney, oesophageal, and bladder cancers.
Cofactor Genomics’ diagnostics platform improves immunotherapy response predictions, helping identify patients who can avoid chemotherapy and its harmful side effects.
